Anzeige
Mehr »
Montag, 17.08.2026 - Börsentäglich über 12.000 News
100%iger Erfolg - in 70 Tagen Querschnittslähmung geheilt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4205C | ISIN: CH1476899161 | Ticker-Symbol: J8L0
Frankfurt
17.08.26 | 15:25
1,546 Euro
-7,09 % -0,118
1-Jahres-Chart
VERAXA BIOTECH AG Chart 1 Jahr
5-Tage-Chart
VERAXA BIOTECH AG 5-Tage-Chart

Aktuelle News zur VERAXA BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
05.08.Veraxa Biotech Holding AG - F-1/A, Registration statement for certain foreign private issuers16
31.07.Veraxa Biotech Holding AG - F-1, Registration statement for certain foreign private issuers5
29.07.Veraxa Biotech files first BiTAC patent applications in 20263
29.07.Veraxa Biotech AG: VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates828First BiTAC-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology...
► Artikel lesen
27.07.Veraxa advances cancer therapy program with OmniAb10
VERAXA BIOTECH Aktie jetzt für 0€ handeln
27.07.Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb415VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies...
► Artikel lesen
27.07.Veraxa treibt Krebstherapie-Programm mit OmniAb voran9
27.07.Veraxa Biotech Holding AG - 6-K, Report of foreign issuer2
24.07.Veraxa Biotech shareholders approve governance changes3
24.07.Veraxa Biotech: Aktionäre genehmigen weitreichende Satzungsänderungen15
24.07.Veraxa Biotech AG: VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth713ZURICH, SWITZERLAND, July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in the design and development of next-generation cancer therapeutics, held an Extraordinary...
► Artikel lesen
23.07.Veraxa Biotech names Christoph Erkel as chief scientific officer4
23.07.Veraxa Biotech AG: VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Technology Platforms and Portfolio455ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph...
► Artikel lesen
20.07.Veraxa Biotech AG - 6-K, Report of foreign issuer2
20.07.Veraxa Biotech AG: VERAXA Biotech Announces Regulatory Progress with its BiTAC-TCE Development Plan800ZURICH, SWITZERLAND - July 20, 2026 - VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from...
► Artikel lesen
13.07.Veraxa kooperiert mit Ardigen bei KI-gestützter Auswahl von Krebs-Targets5
13.07.Veraxa Biotech AG: VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC Pipeline581Ardigen platform supports VERAXA's in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs)ZURICH, SWITZERLAND...
► Artikel lesen
10.07.VERAXA Biotech names Carl von Halem as interim CFO3
10.07.VERAXA Biotech appoints interim CFO4
10.07.VERAXA Biotech AG: VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister626ZURICH, SWITZERLAND - July 10, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim...
► Artikel lesen
Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1